Literature DB >> 22859398

Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.

Paul J Dluzniewski1, Ming-Hsi Wang, Siqun Lilly Zheng, Angelo M De Marzo, Charles G Drake, Helen L Fedor, Alan W Partin, Misop Han, M Daniele Fallin, Jianfeng Xu, William B Isaacs, Elizabeth A Platz.   

Abstract

BACKGROUND: To evaluate the association of variation in genes involved in immune response, including IL10, production and detoxification of reactive oxygen species, and repair of oxidative DNA damage with risk of recurrence after surgery for localized prostate cancer.
METHODS: We conducted a nested case-control study of men who had a radical prostatectomy in 1993 to 2001. A total of 484 recurrence cases and 484 controls were matched on age, race, and pathologic stage and grade. Germline DNA was extracted from paraffin-embedded unaffected lymph nodes. We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3. We used conditional logistic regression to estimate OR and 95% confidence intervals (CI).
RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91). We also observed associations for candidate SNPs in CRP, GSTP1, and IL1B. A common IL10 haplotype and 2 common NOS2 haplotypes were associated with recurrence.
CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors. IMPACT: This study supports that genetic variation in immune response and oxidation influence prostate cancer recurrence risk and suggests genetic variation in these pathways may inform prognosis. 2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859398      PMCID: PMC3467312          DOI: 10.1158/1055-9965.EPI-12-0458

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  40 in total

1.  Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.

Authors:  Ilir Agalliu; Wendy J Langeberg; Johanna W Lampe; Claudia A Salinas; Janet L Stanford
Journal:  Prostate       Date:  2006-02-01       Impact factor: 4.104

2.  Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.

Authors:  M V Cronauer; Y Ince; R Engers; L Rinnab; W Weidemann; C V Suschek; M Burchardt; H Kleinert; J Wiedenmann; H Sies; R Ackermann; K-D Kröncke
Journal:  Oncogene       Date:  2006-09-18       Impact factor: 9.867

Review 3.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Relation of polymorphism within the C-reactive protein gene and plasma CRP levels.

Authors:  H Jacqueline Suk; Paul M Ridker; Nancy R Cook; Robert Y L Zee
Journal:  Atherosclerosis       Date:  2005-01       Impact factor: 5.162

5.  Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels.

Authors:  Christopher S Carlson; Shelley Force Aldred; Philip K Lee; Russell P Tracy; Stephen M Schwartz; Mark Rieder; Kiang Liu; O Dale Williams; Carlos Iribarren; E Cora Lewis; Myriam Fornage; Eric Boerwinkle; Myron Gross; Cashell Jaquish; Deborah A Nickerson; Richard M Myers; David S Siscovick; Alexander P Reiner
Journal:  Am J Hum Genet       Date:  2005-05-16       Impact factor: 11.025

6.  Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events.

Authors:  Leslie A Lange; Christopher S Carlson; Lucia A Hindorff; Ethan M Lange; Jeremy Walston; J Peter Durda; Mary Cushman; Joshua C Bis; Donglin Zeng; Danyu Lin; Lewis H Kuller; Deborah A Nickerson; Bruce M Psaty; Russell P Tracy; Alexander P Reiner
Journal:  JAMA       Date:  2006-12-13       Impact factor: 56.272

7.  Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer.

Authors:  Dominique S Michaud; Sarah E Daugherty; Sonja I Berndt; Elizabeth A Platz; Meredith Yeager; E David Crawford; Ann Hsing; Wen-Yi Huang; Richard B Hayes
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

8.  Association of IL-10 polymorphisms with prostate cancer risk and grade of disease.

Authors:  Jessica M Faupel-Badger; La Creis Renee Kidd; Demetrius Albanes; Jarmo Virtamo; Karen Woodson; Joseph A Tangrea
Journal:  Cancer Causes Control       Date:  2007-11-13       Impact factor: 2.506

9.  C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Authors:  Tomasz M Beer; Alshad S Lalani; Stella Lee; Motomi Mori; Kristine M Eilers; John G Curd; W David Henner; Christopher W Ryan; Peter Venner; J Dean Ruether; Kim N Chi
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

10.  C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study.

Authors:  Kathy J Helzlsouer; Thomas P Erlinger; Elizabeth A Platz
Journal:  Eur J Cancer       Date:  2006-03-02       Impact factor: 9.162

View more
  28 in total

1.  Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Authors:  Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz
Journal:  Clin Chem       Date:  2018-12-05       Impact factor: 8.327

Review 2.  Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Authors:  Sang Wook Kang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippmann; Howard L Parnes; Paul J Dluzniewski; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz
Journal:  Prostate       Date:  2015-06-05       Impact factor: 4.104

4.  Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Authors:  Qizhi Zheng; Sarah B Peskoe; Judit Ribas; Fatema Rafiqi; Tarana Kudrolli; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold
Journal:  Prostate       Date:  2014-09-22       Impact factor: 4.104

Review 5.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

6.  Genetic variation across C-reactive protein and risk of prostate cancer.

Authors:  Sarah C Markt; Jennifer R Rider; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Katja Fall; Howard D Sesso; Meir J Stampfer; Lorelei A Mucci
Journal:  Prostate       Date:  2014-05-20       Impact factor: 4.104

7.  Genetic variants within endothelial nitric oxide synthase gene and prostate cancer: a meta-analysis.

Authors:  Zorana Z Nikolić; Dušanka Lj Savić Pavićević; Stanka P Romac; Goran N Brajušković
Journal:  Clin Transl Sci       Date:  2014-08-27       Impact factor: 4.689

Review 8.  Interplay between DNA repair and inflammation, and the link to cancer.

Authors:  Dawit Kidane; Wook Jin Chae; Jennifer Czochor; Kristin A Eckert; Peter M Glazer; Alfred L M Bothwell; Joann B Sweasy
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-01-13       Impact factor: 8.250

9.  PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.

Authors:  Chao Wang; Yaping Feng; Chengyue Zhang; David Cheng; Renyi Wu; Yuqing Yang; Davit Sargsyan; Dibyendu Kumar; Ah-Ng Kong
Journal:  FASEB J       Date:  2019-11-29       Impact factor: 5.191

Review 10.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.